I think we see a double dose this year. The psoriasis cream and the sublingual tablet for product on the market.
In addition, I also think we will be getting more info on how the Israel IRB trials fit in with FDA acceptance/approval. That alone is worth quite a bit per share.
(0)
(0)
OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links